Company Overview of Entasis Therapeutics Inc.
Entasis Therapeutics Inc. discovers and develops antibacterials to fight diseases caused by multidrug-resistant bacteria. It offers ETX2514, a broad-spectrum and potent inhibitor of class A, C, and D beta-lactamases that has activity against Acinetobacter baumannii, a gram-negative bacterium that causes severe infections, which are associated with high mortality; ETX0914, a novel oral antibiotic for the treatment of uncomplicated gonorrhea; and a drug discovery platform that focuses on developing novel antibacterials targeting serious gram-negative infections, such as pneumonia, infections of the blood, urinary tract infections, and infections following surgery. The company was founded in 20...
Gatehouse Park BioHub
35 Gatehouse Drive
Waltham, MA 02451
Founded in 2015
Key Executives for Entasis Therapeutics Inc.
Chief Executive Officer, President and Director
Chief Financial Officer, Chief Business Officer and Director
Vice President of Projects & Early Development
Compensation as of Fiscal Year 2017.
Entasis Therapeutics Inc. Key Developments
Entasis Therapeutics and Global Antibiotic Research & Development Partnership to Develop New Treatment for Drug-Resistant Gonorrhea
Jul 6 17
Zoliflodacin, a novel oral antibiotic and one of the only treatments in development to address the threat of drug-resistant gonorrhea will enter pivotal trials, due to a new partnership between Global Antibiotic Research and Development Partnership (GARDP) and Entasis Therapeutics. Entasis and GARDP will co-develop the antibiotic, zoliflodacin, in a global Phase 3 clinical trial to be carried out in countries including South Africa, the United States of America, and Thailand. The US National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), plans to support pharmacological studies on the drug as part of the development programme. In parallel with the Phase 3 trial, which is sponsored by GARDP/DNDi (Drugs for Neglected Diseases initiative), GARDP will work with Entasis scientists to carry out non-clinical activities – including microbiology surveys to ensure that the product is effective against recent and geographically diverse strains of gonorrhea. If zoliflodacin receives regulatory approval, Entasis will grant GARDP an exclusive license with sublicensing rights in most low- and middle-income countries, while retaining commercial rights in high-income markets. Both GARDP and Entasis are committed to affordable and equitable pricing in their respective territories.
Entasis Therapeutics Inc. Publishes Data Highlighting the Potent and Differentiated Activity of ETX2514 Combinations Against Drug Resistant Gram-Negative Bacteria Including Acinetobacter and Pseudomonas
Jun 30 17
Entasis Therapeutics Inc. published a report in Nature Microbiology (DOI: 10.1038/nmicrobiol.2017.104) in which Entasis scientists describe the rational design and expanded spectrum activity of ETX2514 against Class A, C, and a broad spectrum of Class D beta-lactamases, important targets in the treatment of resistant bacteria. The report includes the results of in vitro and preclinical in vivo studies, which demonstrate the ability of ETX2514 to restore antimicrobial activity in combination with multiple beta-lactams against Gram-negative, multi-drug resistant (MDR) pathogens. ETX2514 exhibited particularly promising activity in combination with sulbactam against Acinetobacter baumannii, including hard-to-treat carbapenem-resistant and colistin-resistant strains, and with imipenem against carbapenem-resistant Enterobacteriaceae (CRE) and Pseudomonas aeruginosa. The ability of ETX2514 to be administered concurrently with sulbactam and/or imipenem is currently being investigated in a Phase 1 clinical trial.
Entasis Therapeutics Inc. Presents at Jefferies 2017 Global Healthcare Conference, Jun-06-2017 02:00 PM
May 31 17
Entasis Therapeutics Inc. Presents at Jefferies 2017 Global Healthcare Conference, Jun-06-2017 02:00 PM. Venue: Grand Hyatt, 109 E 42nd St, New York, New York, United States. Speakers: Manos Perros, Chief Executive Officer, President and Director.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|